In the BioHarmony Drug Report Database

"Preview" Icon

Linagliptin

Tradjenta, Trajenta (linagliptin) is a small molecule pharmaceutical. Linagliptin was first approved as Tradjenta on 2011-05-02. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against dipeptidyl peptidase 4. Tradjenta’s patents are valid until 2031-03-05 (FDA).

 

Trade Name

 

Trajenta
 

Common Name

 

linagliptin
 

ChEMBL ID

 

CHEMBL237500
 

Indication

 

type 2 diabetes mellitus
 

Drug Class

 

Dipeptidyl aminopeptidase-IV inhibitors

Image (chem structure or protein)

Linagliptin structure rendering